[Editorial] GoGoVax dispels hopes for gonorrhoea vaccination
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00126-X/fulltext?rss=yes

In 2020, WHO estimated that there were 82·4 million new infections with Neisseria gonorrhoeae among adults aged 15–49 years and up to 2022, the incidence of gonorrhoea had been on the rise globally for a decade. While in the last three years a decrease in the number of cases has been observed in several countries, including the USA and the UK, with antimicrobial resistance constituting a major barrier to treatment and no gonorrhoea vaccine available, protecting populations at risk from the disease remains a challenge.

[Corrections] Correction to Lancet Infect Dis 2026; 26: 343–61
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00124-6/fulltext?rss=yes

GBD 2023 Lower Respiratory Infections and Antimicrobial Resistance Collaborators. Global burden of lower respiratory infections and aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet Infect Dis 2026; 26: 343–61—In the Declaration of interests section of this Article, the statement has been corrected for Bogdan Oancea. This correction has been made to the online version as of March 25, 2026, and the printed version is correct.

[Newsdesk] Research in brief
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00129-5/fulltext?rss=yes

A phase 2 randomised trial compared a full or half dose of a live-attenuated chikungunya vaccine (VLA1553) versus an active control (meningococcal vaccine) in 304 children aged 1–11 years in Honduras and the Dominican Republic. Up to 14 days after vaccination, there were no significant between-group differences in incidence or severity of solicited adverse events (AEs). The most common unsolicited AEs through 28 days after vaccination were infections and infestations, occurring in 10·0–20·5% of participants.

Enhanced Detection of Coccidioides spp. Fungi from Environmental Samples Using Droplet Digital PCR

https://wwwnc.cdc.gov/eid/article/32/4/25-1146_article

Confirming ERVEBO Vaccination to Support Ebola Virus Surveillance

https://wwwnc.cdc.gov/eid/article/32/4/25-1906_article

Seroprevalence of Crimean-Congo Hemorrhagic Fever Virus Infection in Humans and Domestic Ruminants, Democratic Republic of the Congo

https://wwwnc.cdc.gov/eid/article/32/4/25-0969_article

Who is this person and what did she accomplish?

https://wwwnc.cdc.gov/eid/article/32/4/25-1083_article

Anopheles stephensi [ә-nah′-fuhl-ēz ste′-fen-zī]

https://wwwnc.cdc.gov/eid/article/32/4/24-1933_article

Geographically Distinct Circulation of Genotype II and III St. Louis Encephalitis Virus, Texas, USA, 2009–2024

https://wwwnc.cdc.gov/eid/article/32/4/25-0934_article

Border Region Surveillance of Malaria Drug Resistance, Northern Burundi, 2023–2024

https://wwwnc.cdc.gov/eid/article/32/4/25-1711_article

Evaluation of Effectiveness of Autocidal Gravid Ovitraps for Preventing Zika Virus Infection, Puerto Rico, USA

https://wwwnc.cdc.gov/eid/article/32/4/25-1206_article

Tropism and Replication Competence of Cattle Influenza A(H5N1) Genotype B3.13 Virus in Human Bronchus and Lung Tissue

https://wwwnc.cdc.gov/eid/article/32/5/25-1926_article

[Comment] Structural stigma: an urgent intervention priority in Africa
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(25)00359-5/fulltext?rss=yes

Improved access to antiretroviral therapy (ART) for people with HIV has greatly affected the trajectory of the global HIV pandemic, enabling people with HIV to lead long, healthy lives and curtailing the number of people who newly acquire HIV. Between 2000 and 2024, the number of people with HIV accessing ART globally increased from 370 000 to 31·6 million.1 Over the same period, the percentage of people with HIV accessing ART increased from 0% to 83% in Africa,2 a region that accounts for nearly two-thirds of the 40·8 million people with HIV worldwide.

Accelerated Increase in Candida auris Bloodstream Infections during COVID-19 Pandemic, South Africa

https://wwwnc.cdc.gov/eid/article/32/4/25-1407_article

Ecologic Investigative Strategies to Determine Human Plague Exposure Sites, United States, 1991–2018

https://wwwnc.cdc.gov/eid/article/32/4/25-1357_article

Dengue Incidence, Seroprevalence, and Expansion Factors from Active Surveillance, Brazil, 2016–2021

https://wwwnc.cdc.gov/eid/article/32/4/25-0942_article

Investigation of and Response to Autochthonous Dengue, Los Angeles County, California, USA, August–November 2024

https://wwwnc.cdc.gov/eid/article/32/5/25-1812_article

Circulation Patterns, Genetic Diversity, and Public Health Implications of Enterovirus D68, Europe, 2014–2024

https://wwwnc.cdc.gov/eid/article/32/4/25-1022_article

Transmissibility and Disease Progression of Asymptomatic Mycobacterium tuberculosis Infection, Lima, Peru

https://wwwnc.cdc.gov/eid/article/32/4/25-1947_article

Whole-Genome Analysis of Treponema pallidum subsp. endemicum among Men Who Have Sex with Men, Japan, 2020–2023

https://wwwnc.cdc.gov/eid/article/32/4/25-1045_article

Acute Febrile Illness Surveillance for Estimating Population Immunity, Dominican Republic, 2021

https://wwwnc.cdc.gov/eid/article/32/4/25-1205_article